AN-2690, a novel antifungal for the topical treatment of onychomycosis.
Schering-Plough Corp, under license from Anacor Pharmaceuticals Inc, is developing AN-2690, an antifungal agent with activity against Trichophyton species, in a topical solution formulation, for the potential treatment of onychomycosis. Phase II and IIb trials with AN-2690 are underway.
Tufts-New England Medical Center, Department of Dermatology, 750 Washington Street, Boston, MA 02111, USA.
Orr
O
Barak
Daniel S
DS
Loo
D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D001896:Boron Compounds / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D014009:Onychomycosis / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D014249:Trichophyton / Q000187:drug effects
D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; C512998:tavaborole